These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33850132)

  • 1. Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden.
    Zhu G; Guo YA; Ho D; Poon P; Poh ZW; Wong PM; Gan A; Chang MM; Kleftogiannis D; Lau YT; Tay B; Lim WJ; Chua C; Tan TJ; Koo SL; Chong DQ; Yap YS; Tan I; Ng S; Skanderup AJ
    Nat Commun; 2021 Apr; 12(1):2229. PubMed ID: 33850132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA.
    Gawroński AR; Lin YY; McConeghy B; LeBihan S; Asghari H; Koçkan C; Orabi B; Adra N; Pili R; Collins CC; Sahinalp SC; Hach F
    Nucleic Acids Res; 2019 Apr; 47(7):e38. PubMed ID: 30759232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
    van 't Erve I; Medina JE; Leal A; Papp E; Phallen J; Adleff V; Chiao EJ; Arun AS; Bolhuis K; Simmons JK; Karandikar A; Valkenburg KC; Sausen M; Angiuoli SV; Scharpf RB; Punt CJA; Meijer GA; Velculescu VE; Fijneman RJA
    Clin Cancer Res; 2023 Mar; 29(5):899-909. PubMed ID: 36534496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.
    Lee DW; Lim Y; Kim HP; Kim SY; Roh H; Kang JK; Lee KH; Kim MJ; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Cancer Res Treat; 2023 Jul; 55(3):927-938. PubMed ID: 36915247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
    Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
    Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological Assessment of Stent Placement for Obstructive Colorectal Cancer from Circulating Cell-Free DNA and Circulating Tumor DNA Dynamics.
    Takahashi G; Yamada T; Iwai T; Takeda K; Koizumi M; Shinji S; Uchida E
    Ann Surg Oncol; 2018 Mar; 25(3):737-744. PubMed ID: 29235008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.
    Morris VK; Strickler JH
    Annu Rev Med; 2021 Jan; 72():399-413. PubMed ID: 33502901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
    Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
    Helzer KT; Sharifi MN; Sperger JM; Shi Y; Annala M; Bootsma ML; Reese SR; Taylor A; Kaufmann KR; Krause HK; Schehr JL; Sethakorn N; Kosoff D; Kyriakopoulos C; Burkard ME; Rydzewski NR; Yu M; Harari PM; Bassetti M; Blitzer G; Floberg J; Sjöström M; Quigley DA; Dehm SM; Armstrong AJ; Beltran H; McKay RR; Feng FY; O'Regan R; Wisinski KB; Emamekhoo H; Wyatt AW; Lang JM; Zhao SG
    Ann Oncol; 2023 Sep; 34(9):813-825. PubMed ID: 37330052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combining Effects of Cell-Free Circulating Tumor DNA of Breast Tumor to the Noninvasive Prenatal Testing Results: A Simulating Investigation.
    Cai YH; Yao GY; Chen LJ; Gan HY; Ye CS; Yang XX
    DNA Cell Biol; 2018 Jul; 37(7):626-633. PubMed ID: 29957029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for Measuring ctDNA in Lymphomas.
    Rossi D; Condoluci A; Spina V; Gaidano G
    Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer.
    Tian J; Geng Y; Lv D; Li P; Cordova M; Liao Y; Tian X; Zhang X; Zhang Q; Zou K; Zhang Y; Zhang X; Li Y; Zhang J; Ma Z; Shao Y; Song L; Owen GI; Li T; Liu R; Liu Q; Zou L; Zhang Z; Li Z
    Int J Cancer; 2019 Nov; 145(9):2547-2557. PubMed ID: 30919951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.